Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient was told to return on day seven for Rabavert second dose but did not return until day 21; Case reference number US-BN-2025-001199 is a spontaneous case initially received from nurse via agency (reference number: USBAV25-1661) on 09-Jul-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On unspecified date, the patient received the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route or site of administration for unknown indication. As reported, the patient was told to return on day seven for Rabavert second dose but did not return until day 21 (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns a female patient of unspecified age, who received the first dose of RabAvert for unknown indication, but did not return for second dose until day 21, which is considered as 'incomplete course of vaccination'. Incomplete course of vaccination is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any of adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a female patient of unspecified age, who received the first dose of RabAvert for unknown indication, but did not return for second dose until day 21, which is considered as 'incomplete course of vaccination'. Incomplete course of vaccination is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any of adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.